Targacept, Inc. (NASDAQ: TRGT) today announced positive top-line results from a double blind, placebo controlled, flexible dose Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment for major depressive disorder, or MDD, in subjects who did not respond adequately to first-line treatment with citalopram alone.
Popularity: unranked [?]
Related posts:
- Targacept Presents Data From Highly Successful Phase 2b Trial Of TC-5214 As Augmentation Treatment For Major Depressive Disorder
- Targacept Presents Data From Highly Successful Phase 2b Trial Of TC-5214 As Augmentation Treatment For Major Depressive Disorder
- Targacept Starts Phase 2b Clinical Trial Of TC-5214 As Augmentation Treatment In Major Depressive Disorder
- Targacept Announces Positive Results Of Phase II Clinical Trial In Major Depression
- DOV Pharmaceutical, Inc. Initiates Phase II Clinical Trial In Patients With Major Depressive Disorder
Comments
No Responses to “Targacept’s TC-5214 Achieves All Primary And Secondary Outcome Measures In Phase 2b Trial As Augmentation Treatment For Major Depressive Disorder”